These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 7779715)
21. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Gu J; Kawai H; Wiederschain D; Yuan ZM Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491 [TBL] [Abstract][Full Text] [Related]
22. Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining. MacGeoch C; Turner G; Bobrow LG; Barnes DM; Bishop DT; Spurr NK J Med Genet; 1995 Mar; 32(3):186-90. PubMed ID: 7783166 [TBL] [Abstract][Full Text] [Related]
23. Chromosome instability in fibroblasts derived from Li-Fraumeni syndrome families without TP53 mutations. Boyle JM; Spreadborough A; Greaves MJ; Birch JM; Scott D Br J Cancer; 2000 Nov; 83(9):1136-8. PubMed ID: 11027425 [TBL] [Abstract][Full Text] [Related]
24. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931 [TBL] [Abstract][Full Text] [Related]
25. G2 chromosomal radiosensitivity in fibroblasts of ataxia-telangiectasia heterozygotes and a Li-Fraumeni syndrome patient with radioresistant cells. Mitchell EL; Scott D Int J Radiat Biol; 1997 Oct; 72(4):435-8. PubMed ID: 9343108 [TBL] [Abstract][Full Text] [Related]
26. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes. Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481 [TBL] [Abstract][Full Text] [Related]
27. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Siddiqui R; Onel K; Facio F; Nafa K; Diaz LR; Kauff N; Huang H; Robson M; Ellis N; Offit K Fam Cancer; 2005; 4(2):177-81. PubMed ID: 15951970 [TBL] [Abstract][Full Text] [Related]
28. Fibroblasts from Li-Fraumeni patients are resistant to low dose-rate irradiation. Sproston AR; Boyle JM; Heighway J; Birch JM; Scott D Int J Radiat Biol; 1996 Aug; 70(2):145-50. PubMed ID: 8794843 [TBL] [Abstract][Full Text] [Related]
29. Deficiency in the repair of UV-induced DNA damage in human skin fibroblasts compromised for the ATM gene. Hannan MA; Hellani A; Al-Khodairy FM; Kunhi M; Siddiqui Y; Al-Yussef N; Pangue-Cruz N; Siewertsen M; Al-Ahdal MN; Aboussekhra A Carcinogenesis; 2002 Oct; 23(10):1617-24. PubMed ID: 12376469 [TBL] [Abstract][Full Text] [Related]
30. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457 [TBL] [Abstract][Full Text] [Related]
31. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Srivastava S; Zou ZQ; Pirollo K; Blattner W; Chang EH Nature; 1990 Dec 20-27; 348(6303):747-9. PubMed ID: 2259385 [TBL] [Abstract][Full Text] [Related]
32. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982 [TBL] [Abstract][Full Text] [Related]
33. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212 [TBL] [Abstract][Full Text] [Related]
34. A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. Camplejohn RS; Perry P; Hodgson SV; Turner G; Williams A; Upton C; MacGeoch C; Mohammed S; Barnes DM Br J Cancer; 1995 Sep; 72(3):654-62. PubMed ID: 7669577 [TBL] [Abstract][Full Text] [Related]
35. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family. Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898 [TBL] [Abstract][Full Text] [Related]
36. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome. Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309 [TBL] [Abstract][Full Text] [Related]
37. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours. Sedlacek Z; Kodet R; Kriz V; Seemanova E; Vodvarka P; Wilgenbus P; Mares J; Poustka A; Goetz P Br J Cancer; 1998 Apr; 77(7):1034-9. PubMed ID: 9569035 [TBL] [Abstract][Full Text] [Related]
38. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208 [TBL] [Abstract][Full Text] [Related]
39. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930 [TBL] [Abstract][Full Text] [Related]